Congress

Immunotherapy Bridge 2021

Register here

December 1-2 2021

6:10 PM CEST

Naples Italy

Lunaphore at Immunotherapy Bridge 2022

Join us at the Immunotherapy bridge hybrid meeting on December 1-2, 2021 and attend our exclusive roundtable!

December 2, 2021

Roundtable discussion

6:10 PM CEST

Naples

Background:
Cancer therapies based on immune checkpoint inhibitors have aroused as new therapeutic strategies in recent decades, and are finally achieving a significant treatment efficacy. Limited knowledge on both treatment mechanisms and tumor heterogeneity entangles the clinical decision on which combination of immunotherapies to be used and which patient would benefit the most.

Aim:
Essential premise for precision medicine holds the dissection of the components and the features of local tumor milieu in each individual patient. Spatial Omics technologies such as multiplex-immunohistochemistry staining are emerging at frantic pace as a tool to demystify the landscape description of the cancer immune-contexture.

Conclusion:
In situ biomarker analyses acts as game changer to deepen the status quo about the mechanisms of response and resistance to different immunotherapy combinations. Sharp understanding of patient stratification based on local tumor dynamics will eventually benefit cancer patients substantially.

Speakers

Prof. Dr. Paolo A. Ascierto

Prof. Dr. Paolo A. Ascierto

Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department

National Cancer Institute “Fondazione G. Pascale

Prof. Paolo Ascierto is a world-leading key opinion leader in immunotherapy. He is currently the Director of the Department of Melanoma, Cancer Immunotherapy, and Development Therapeutics at the National Cancer Institute in Naples, Italy. He is a Scientific Reviewer for leading medical journals and a Member of the Society of Melanoma Research’s Steering Committee. Dr. Ascierto is part of the Board of Directors for SITC and President of the Fondazione Melanoma Onlus & Campania Society of ImmunoTherapy of Cancer. He has presided as PI on over 150 clinical trials and is the author of more than 600 publications in peer-reviewed journals.

Dr. Carlo Bifulco

Dr. Carlo Bifulco

Medical Director, PSJH System Genomics Laboratory, Providence St. Joseph Health, Director and Member, Translational Molecular Pathology, Earle A. Chiles Research Institute

Providence Cancer Institute

Dr. Bifulco serves on the Global Colon Cancer Immunoscore Task Force led by the Society for Immunotherapy of Cancer (SITC) and is co-Chair of the SITC Pathology Task convened to establish multiplexed immunohistochemistry/immunofluorescence (mIHC/IF) standards.

Dr. Jerome Galon

Dr. Jerome Galon

INSERM Laboratory of Integrative Cancer Immunology

Sorbonne University, University of Paris, France

Related Events